INSMED INC (INSM)

US4576693075 - Common Stock

24.86  -0.06 (-0.24%)

Buy % Consensus

85

ChartMill assigns a Buy % Consensus number of 85% to INSM. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 44.74. This target is 79.98% above the current price.
INSM was analyzed by 22 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about INSM.
In the previous month the buy percentage consensus was at a similar level.
INSM was analyzed by 22 analysts, which is quite many. So the average rating should be quite meaningful.

Price Target & Forecast

Price Low Median Mean High 24.8635.3542.8444.7457.75 - 42.20% 72.33% 79.98% 132.30%
Up and Down Grades
Date Firm Action Rating
2024-04-23 Truist Securities Initiate Buy
2024-04-11 Barclays Maintains Overweight -> Overweight
2024-04-01 Wells Fargo Maintains Overweight -> Overweight
2024-02-27 Guggenheim Maintains Buy -> Buy
2024-02-27 UBS Initiate Buy
2024-02-15 Wolfe Research Initiate Outperform
2023-11-20 JP Morgan Reiterate Overweight
2023-09-21 Cantor Fitzgerald Maintains Overweight -> Overweight
2023-09-19 Cantor Fitzgerald Reiterate Overweight -> Overweight
2023-09-07 Evercore ISI Group Maintains Outperform -> Outperform
2023-09-06 B of A Securities Maintains Buy -> Buy
2023-09-06 HC Wainwright & Co. Reiterate Buy -> Buy
2023-09-05 Guggenheim Reiterate Buy -> Buy
2023-08-04 Morgan Stanley Reiterate Overweight -> Overweight
2023-08-04 HC Wainwright & Co. Reiterate Buy -> Buy
2023-07-26 Guggenheim Initiate Buy
2023-05-09 HC Wainwright & Co. Reiterate Buy
2023-02-24 Cantor Fitzgerald Maintains Overweight
2023-02-24 Credit Suisse Reiterate Outperform
2023-02-24 HC Wainwright & Co. Reiterate Buy
2023-01-20 Barclays Maintains Overweight
2023-01-09 Goldman Sachs Maintains Buy
2022-12-09 Mizuho Initiate Buy
2022-12-08 Barclays Initiate Overweight
2022-12-07 Barclays Initiate Overweight
2022-11-18 B of A Securities Initiate Buy
2022-10-27 SVB Leerink Maintains Outperform
2022-10-25 Cantor Fitzgerald Maintains Overweight
2022-10-21 Cowen & Co. Maintains Outperform
2022-07-15 Morgan Stanley Maintains Overweight